



Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey)

Erküner, Ö.; Dudink, E.A.M.P.; Nieuwlaat, R.; Rienstra, M.; Van Gelder, I.C.; Camm, A.J.; Capucci, A.; Breithardt, G.; LeHeuzey, J.-Y.; Lip, G.Y.H.; Crijns, H.J.G.M.; Luermans, J.G.L.M.

Published in:
American Journal of Cardiology

DOI (link to publication from Publisher):
[10.1016/j.amjcard.2018.04.053](https://doi.org/10.1016/j.amjcard.2018.04.053)

Creative Commons License
CC BY-NC-ND 4.0

Publication date:
2018

Document Version
Publisher's PDF, also known as Version of record

[Link to publication from Aalborg University](#)

Citation for published version (APA):

Erküner, Ö., Dudink, E. A. M. P., Nieuwlaat, R., Rienstra, M., Van Gelder, I. C., Camm, A. J., Capucci, A., Breithardt, G., LeHeuzey, J.-Y., Lip, G. Y. H., Crijns, H. J. G. M., & Luermans, J. G. L. M. (2018). Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey). *American Journal of Cardiology*, 122(4), 578-583.
<https://doi.org/10.1016/j.amjcard.2018.04.053>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

Take down policy

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.

Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey)



Ömer Erküner, MD^{a,b,*}, Elton A.M.P. Dudink, MD^{a,b}, Robby Nieuwlaat, MSc, PhD^c, Michiel Rienstra, MD PhD^d, Isabelle C. Van Gelder, MD PhD^d, A. John Camm, MD^e, Alessandro Capucci, MD PhD^f, Günter Breithardt, MD, PhD^g, Jean-Yves LeHeuzey, MD^h, Gregory Y.H. Lip, MD^{i,j}, Harry J.G.M. Crijns, MD PhD^{a,b}, and Justin G.L.M. Luermans, MD PhD^a

Hypertension is a risk factor for both progression of atrial fibrillation (AF) and development of AF-related complications, that is major adverse cardiac and cerebrovascular events (MACCE). It is unknown whether left ventricular hypertrophy (LVH) as a consequence of hypertension is also a risk factor for both these end points. We aimed to assess this in low-risk AF patients, also assessing gender-related differences. We included 799 patients from the Euro Heart Survey with nonvalvular AF and a baseline echocardiogram. Patients with and without hypertension were included. End points after 1 year were occurrence of AF progression, that is paroxysmal AF becoming persistent and/or permanent AF, and MACCE. Echocardiographic LVH was present in 33% of 379 hypertensive patients. AF progression after 1 year occurred in 10.2% of 373 patients with rhythm follow-up. In hypertensive patients with LVH, AF progression occurred more frequently as compared with hypertensive patients without LVH (23.3% vs 8.8%, $p = 0.011$). In hypertensive AF patients, LVH was the most important multivariably adjusted determinant of AF progression on multivariable logistic regression (odds ratio 4.84, 95% confidence interval 1.70 to 13.78, $p = 0.003$). This effect was only seen in male patients (27.5% vs 5.8%, $p = 0.002$), while in female hypertensive patients, no differences were found in AF progression rates regarding the presence or absence of LVH (15.2% vs 15.0%, $p = 0.999$). No differences were seen in MACCE for hypertensive patients with and without LVH. In conclusion, in men with hypertension, LVH is associated with AF progression. This association seems to be absent in hypertensive women. © 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license. (<http://creativecommons.org/licenses/by-nc-nd/4.0/>) (Am J Cardiol 2018;122:578–583)

^aMaastricht University Medical Center (MUMC+), Department of Cardiology, Maastricht, The Netherlands; ^bCardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands; ^cMcMaster University Hamilton, Department of Clinical Epidemiology and Biostatistics, Ontario, Canada; ^dUniversity of Groningen, University Medical Center Groningen, Thoraxcenter, Department of Cardiology, Groningen, The Netherlands; ^eMolecular and Clinical Sciences Research Institute, Cardiology Clinical Academic Group, St George's University of London, and St George's Hospital, University of London, Department of Cardiology, London, United Kingdom; ^fMarche Polytechnic University of Ancona, Department of Cardiology, Ancona, Italy; ^gUniversity Hospital Münster, Division of Clinical and Experimental Electrophysiology, Department of Cardiovascular Medicine, Münster, Germany; ^hHôpital Européen Georges Pompidou, Université Paris Descartes, Department of Cardiology, Paris, France; ⁱInstitute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom; and ^jAalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. Manuscript received February 6, 2018; revised manuscript received and accepted April 19, 2018.

This work was supported by the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation [CVON 2014-9, RACE V: "Reappraisal of Atrial Fibrillation: interaction between hyperCoagulability, Electrical remodeling, and Vascular destabilisation in the progression of AF" to Ö.E., M.R., I.C.V.G., H.J.G.M.C., and J.G.L.M.L.].

See page 582 for disclosure information.

*Corresponding author: Tel: 0031-433871612; fax: 0031-433877081.

E-mail address: omer.erkuner@mumc.nl (Ö. Erküner).

0002-9149/© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license. (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

<https://doi.org/10.1016/j.amjcard.2018.04.053>

Atrial fibrillation (AF) is associated with several co-morbidities, the most prevalent being hypertension, affecting 49% to 90% of AF patients.¹ Hypertension is a risk factor for both the development² and the progression of AF.^{3,4} Moreover, hypertension is a risk factor for the development of AF-related complications, such as major adverse cardiac and cerebrovascular events (MACCE).⁵ Paroxysmal AF progresses to persistent or permanent AF in 8.6% to 22% of patients after 1 year, depending on the underlying co-morbidities.^{6,7} AF progression is not merely an arrhythmic phenomenon, but it is also associated with a higher rate of ischemic stroke, that is 2% to 4% per year for paroxysmal, persistent and permanent AF, respectively.⁸ Furthermore, AF progression has been associated with hospitalization and all-cause mortality in a primary care study.⁹ Although the relation of hypertension with AF progression and MACCE is clearly established, it is unknown whether hypertensive end organ damage, that is left ventricular hypertrophy (LVH), is also associated with these end points and whether this differs across gender. We hypothesized patients with LVH as a result of hypertension show more AF progression and subsequent occurrence of MACCE compared with hypertensive AF patients without LVH and nonhypertensive patients. Furthermore, we aimed to investigate whether this differs across gender.

www.ajconline.org

Methods

A detailed description of the methods and results of the Euro Heart Survey (EHS) on AF has previously been published.^{10,11} In summary, the EHS is a prospective registry conducted 2003 to 2005 in 182 hospitals across 35 member countries of the European Society of Cardiology. All centers obtained approval from their Institutional Committee on Human Research. Consecutive in and outpatients with (Holter) electrocardiogram proved AF were included after providing written informed consent. One-year follow-up was completed in 3,978 of the included 5,333 patients.

We included 799 patients from the EHS with nonvalvular, paroxysmal AF, and a baseline echocardiogram. Patients with and without hypertension were selected. Since we aimed to assess the relation of hypertension and LVH with the end points of AF progression and MACCE, we tried to diminish the influence of other factors related to these end points as much as possible. This was done by excluding patients with other stroke risk factors, that is congestive heart failure, age ≥ 65 years, diabetes mellitus, previous stroke and/or transient ischemic attack, and vascular disease.

The occurrence of AF progression and MACCE after 1 year was assessed separately for the groups with and without hypertension, subdivided by the presence of echocardiographic LVH. Gender differences were also evaluated. Hypertension was defined as the presence of systolic blood pressure (BP) at rest of >140 mm Hg or diastolic BP of >90 mm Hg on ≥ 2 occasions or current antihypertensive drug treatment. The presence or absence of echocardiographic LVH was assessed by the treating physician. AF progression was defined as paroxysmal AF at baseline becoming persistent or permanent AF after 1 year of follow-up, like previously defined by de Vos et al⁴ and MACCE was defined as cardiovascular death, stroke, transient ischemic attack, systemic thromboembolism, myocardial infarction, or major bleeding (hemorrhagic stroke or bleeding requiring hospitalization, causing a hemoglobin level decrease of 2 g/l or requiring blood transfusion). Patients with missing data were excluded and a complete-case analysis was performed.

Data were analyzed with SPSS statistical software (version 22.0, SPSS Inc., Chicago, Illinois). Continuous variables are reported as mean \pm standard deviation if normally distributed and as median and inter quartile range if not. Normally distributed continuous variables were compared between groups using the independent samples *t* test, whereas not normally distributed continuous variables were compared using the Mann–Whitney U test. Categorical variables are reported as observed number of patients and percentage. Amonggroup comparisons were made using a chi-square test. Fisher's exact test was used in case of any expected cell count <5 . All baseline characteristics with a significant univariate association ($p < 0.10$) with one of the end points were incorporated into a multivariable logistic regression model with stepwise reduction of the model by excluding variables with $p > 0.10$. All variables in the final model were tested for interactions. Remaining variables with $p < 0.05$ were considered significant independent determinants for the end points of AF progression and the occurrence of MACCE.

Results

Of the 799 included patients, rhythm follow-up was available in 47% and information on the occurrence of MACCE in 76%. The majority of the patients was men (73%), mean age was 52 ± 10 years. AF progression occurred in 38 (10.2%) of 373 patients, whereas MACCE occurred in 21 (3.4%) of 610 patients. Hypertension was present in 47%. In general, hypertensive AF patients showed more AF progression (14.2% vs 7.1%, $p = 0.025$) as well as MACCE (5.3% vs 1.8%, $p = 0.018$), compared with the normotensives (Figure 1).

LVH was present in 124 (33%) of 379 hypertensive patients and in 51 (12%) of 420 normotensive AF patients. The baseline characteristics of the included patients, subdivided by the presence of hypertension and LVH, are presented in Table 1, together with the occurrence of the end points for all groups. In patients without hypertension, no differences in AF progression and in the development of MACCE could be ascertained when comparing patients with LVH to those without (Figure 2).

Hypertensive patients with echocardiographic LVH at baseline (124 of 379) had on average a higher body mass index and were more frequently on calcium antagonist and angiotensin converting enzyme inhibitors, compared with hypertensive patients without LVH (Table 1). AF progression at 1 year was significantly more prevalent in patients with LVH (23.3% vs 8.8%, $p = 0.011$), whereas no differences were found in the development of MACCE (4.5% vs 5.7%, $p = 0.782$; Figure 2).

Several determinants of AF progression were identified using multivariable analysis in the patients with hypertension, the most important being LVH on echocardiography (Table 2). Other independent determinants of AF progression were the use of vitamin K antagonists, age, and diastolic BP. No interactions were present. In hypertensive men, AF progression rates were 27.5% and 5.8% per year in those with and without LVH, respectively, similar to the rates seen in the studied overall cohort. In hypertensive women however, AF progression rates in patients with and without LVH did not differ, that is 15.2% versus 15.0%, $p = 0.999$ (Figure 3). Development of MACCE after 1 year did not differ between men with LVH vs without (3.2% vs 6.1%, $p = 0.507$), and in women (7.4% vs 5.0%, $p = 0.644$).




Figure 1. Differences in AF progression and MACCE rates after 1 year of follow-up for patients with and without hypertension. AF = atrial fibrillation; MACCE = major adverse cardiac and cerebrovascular events.

Table 1

Baseline characteristics and the occurrence of end points for atrial fibrillation patients with and without hypertension, subdivided by the presence of left ventricular hypertrophy on echocardiography

Variable	Systemic hypertension					
	Yes (n = 379)			No (n = 420)		
	No LVH (n = 255)	LVH (n = 124)	p value	No LVH (n = 369)	LVH (n = 51)	p value
Age (years)	56 ± 8	55 ± 8	0.277	50 ± 11	52 ± 9	0.045
Women	80 (31%)	33 (27%)	0.342	94 (26%)	10 (20%)	0.363
Systolic blood pressure	142 ± 21	144 ± 23	0.388	125 ± 15	128 ± 16	0.281
Diastolic blood pressure	88 ± 13	88 ± 13	0.628	78 ± 10	79 ± 12	0.426
Ventricular rate on qualifying electrocardiogram	111 ± 33	109 ± 31	0.658	109 ± 31	108 ± 35	0.874
Body mass index (kg/m ²)	27.8 ± 4.2	28.9 ± 3.7	0.019	26.4 ± 3.9	28.0 ± 4.5	0.008
Left ventricular ejection fraction (%)	55 ± 13	53 ± 13	0.159	56 ± 13	56 ± 14	0.989
Left atrial diameter (mm)	42 ± 7	46 ± 8	0.001	41 ± 8	42 ± 10	0.449
Left atrial diameter index (mm/m ²)	22 ± 4	22 ± 3	0.253	21 ± 4	21 ± 5	0.858
Mitral regurgitation grade 2 and higher	68 (27%)	30 (24%)	0.606	61 (17%)	13 (26%)	0.115
Aortic regurgitation grade 2 and higher	21 (8%)	11 (9%)	0.843	14 (4%)	5 (10%)	0.067
Aortic stenosis*	3 (1.2%)	6 (4.8%)	0.064	2 (0.5%)	2 (3.9%)	0.074
Hyperlipidemia†	83 (34%)	35 (29%)	0.407	68 (19%)	13 (27%)	0.215
Valvular heart disease	17 (7%)	13 (11%)	0.213	28 (8%)	7 (14%)	0.171
Chronic obstructive pulmonary disease	17 (7%)	12 (10%)	0.285	10 (2.7%)	2 (3.9%)	0.647
Renal failure	4 (1.6%)	4 (3.2%)	0.448	0	1 (2.0%)	0.121
Hypothyroidism	13 (5.5%)	6 (5.3%)	0.946	11 (3.2%)	1 (2.0%)	0.999
Hyperthyroidism	15 (6.4%)	3 (2.7%)	0.141	19 (5.5%)	3 (6.1%)	0.745
Current smoker	47 (19%)	28 (23%)	0.302	87 (24%)	4 (8%)	0.009
Current alcohol drinker (≥ 1/week)	154 (64%)	65 (57%)	0.181	209 (62%)	26 (53%)	0.240
Medications						
Vitamin K antagonist	160 (65%)	70 (57%)	0.155	206 (60%)	26 (52%)	0.301
Beta blocker	29 (12%)	16 (13%)	0.736	12 (3.5%)	4 (8.0%)	0.131
Angiotensin converting enzyme inhibitor	129 (52%)	84 (68%)	0.004	43 (13%)	14 (28%)	0.003
Angiotensin receptor blockers	44 (18%)	21 (17%)	0.847	10 (2.9%)	1 (2.0%)	0.999
Dihydropyridine calcium channel blocker	25 (10%)	33 (27%)	0.001	5 (1.4%)	2 (4.0%)	0.218
Diuretic	82 (33%)	46 (37%)	0.440	24 (7%)	4 (8%)	0.768
Any anti-arrhythmic drug	148 (58%)	64 (52%)	0.237	211 (57%)	34 (67%)	0.198
Atrial fibrillation progression at 1 year follow-up (n = 373)	9 (9%)	14 (23%)	0.011	13 (6.8%)	2 (9.5%)	0.649
Major adverse cardiac and cerebrovascular events at 1 year follow-up (n = 610)	11 (5.7%)	4 (4.5%)	0.782	5 (1.7%)	1 (2.9%)	0.494

* Aortic stenosis was defined as progressive narrowing of the aortic valve resulting in the obstructed passage of blood from the left ventricle into the aorta.

† Hyperlipidemia was defined as fasting total cholesterol >240 mg/dl (6.2 mmol/l) or LDL-cholesterol >160 mg/dl (4.1 mmol/l) or treatment with any lipid lowering drugs.




Figure 2. Differences in AF progression and MACCE rates after 1 year for patients with and without hypertension, subdivided by presence of LVH.

AF = atrial fibrillation; LVH = left ventricular hypertrophy; MACCE = major adverse cardiac and cerebrovascular events. * = statistical significance.

In male patients with hypertension, the only independent determinant of AF progression was LVH (OR 6.16, 95% CI 1.81 to 20.99, $p = 0.004$). For female patients, independent determinants were age (OR 1.28 for increments of 1 year, 95% CI 1.02 to 1.61, $p = 0.036$), and diastolic BP (OR 0.93 for increments of 1 mm Hg, 95% CI 0.87 to 0.99, $p = 0.029$). In both hypertensive men and women, the use of VKA was not a determinant for AF progression, in contrast to the overall population. The difference between men and women who were prescribed vitamin K antagonists was statistically significant in the hypertensive patients (66% vs 53%, $p = 0.017$), but not in the normotensives (61% vs 53%, $p = 0.178$).

Discussion

Almost half of the patients in our cohort had a history of hypertension. These patients showed more often AF

Table 2
Univariable and multivariable regression for progression of atrial fibrillation in hypertensive patients

Variable	Univariable regression		Multivariable regression	
	Odds ratio (95% CI)	p value	Odds ratio (95% CI)	p value
Left ventricular hypertrophy	3.15 (1.27-7.80)	0.013	4.84 (1.70-13.78)	0.003
Vitamin K antagonist	2.71 (1.04-7.08)	0.041	3.72 (1.28-10.83)	0.016
Age	1.11 (1.02-1.20)	0.016	1.13 (1.04-1.24)	0.007
Diastolic blood pressure, per mm Hg increase	0.96 (0.93-1.00)	0.058	0.95 (0.91-0.99)	0.017
Left atrial diameter, corrected for body surface area	1.12 (0.99-1.27)	0.076		

progression and MACCE after 1 year compared with patients without hypertension (Figure 1), in accordance with previous data.^{3,5,12} LVH at baseline was present in a third of the patients with hypertension. As hypothesized, a significantly larger proportion of these patients showed AF progression after 1 year when compared with hypertensive patients without LVH on echocardiographic assessment (Figure 2). Recently, Padfield et al have also shown that LVH is one of the determinants of AF progression after a median follow-up of 6 years.¹³ Moreover, the higher progression rate seen in patients with hypertension, could be mainly driven by LVH, since AF progression rates in hypertensive patients without LVH and nonhypertensive patients were comparable (Figure 2). Even after correcting for other factors, LVH remained the most important independent determinant of AF progression in the hypertensive group. Thus, LVH seems to be a key marker for AF progression in hypertensive patients with low-risk AF. However, a difference in the occurrence of MACCE could not be ascertained in these patients, possibly due to the overall low MACCE-rate in this relatively low-risk AF population and follow-up duration of 1 year. In addition, 60% of the patients were on vitamin K antagonists, probably reducing MACCE rates.¹⁴

It is unknown whether this effect of LVH on AF progression is reversible. Hennersdorf et al¹⁵ have shown that the prevalence of paroxysmal AF can be diminished in patients with regression of LVH by treating hypertension, compared with patients with a progression in LVH despite treatment. In that post hoc analysis, 24-hour Holter electrocardiograms were performed at baseline and after a mean of 2 years of antihypertensive treatment. The short time span covered by these Holter electrocardiograms and the absence of a predefined scheme for rhythm follow-up, makes cautious




Figure 3. AF progression rates after 1 year of male and female hypertensive AF patients in absence and presence of LVH.
AF = atrial fibrillation; LVH = left ventricular hypertrophy.

interpretation of these data necessary. However, a similar reduction in AF progression rates could possibly be achieved by adequate treatment of hypertension leading to regression of LVH. Of course, this should be studied in a prospective and randomized manner to draw definite conclusions.

Other independent determinants of AF progression in hypertensive AF patients were use of vitamin K antagonists, age, and diastolic BP. Age is a known risk factor for AF progression and is incorporated in the HATCH-score (Heart failure, Age, previous Transient ischemic attack or stroke, Chronic obstructive pulmonary disease, and Hypertension).^{3,4} The use of VKA however is not a known risk factor for AF progression and the effect we observed may be due to confounding. Since stroke risk scores were not in use during the conduct of this registry, the decision to start antithrombotic therapy was made at the discretion of the treating physician. It is possible that this decision was based on clinical parameters, such as left atrial diameter, left atrial volume, and general health of the patient. An alternative explanation may be that VKA are known to cause vascular calcification in animal models.¹⁶ Since coronary artery calcification in humans is associated with an increased risk of the development of AF, this process may also be associated with AF progression.¹⁷

The last independent determinant was diastolic BP. This effect has not been reported in literature before. Although it may be a chance finding, the protective effect of diastolic BP might in part be explained by the relatively higher pulse pressure in patients with a lower diastolic BP. Since a higher pulse pressure is indicative of stiffness of the aorta or major arteries and is related to vascular disease, it might play a role in the progression of AF. Pulse pressure is a known risk factor for new-onset AF, whereas in the same study mean arterial pressure was not related to incident AF.¹⁸ Furthermore, pulse pressure, and not mean arterial pressure, was proved to be related to cardiovascular events in older hypertensive patients.¹⁹ However, pulse pressure was not a significant determinant in our analysis.

In patients without hypertension, LVH was present in a smaller proportion and was not associated with AF progression and MACCE (Figure 2). These patients can be seen as truly low-risk AF, with an overall AF progression rate of 7.1% and a MACCE rate of 1.8% per year, both representing a fairly low risk. However, this could be partially caused by the small group of patients with LVH in the non-hypertensive patients. Perhaps in a larger population, LVH might lead to a higher AF progression rate through diastolic dysfunction and an increase in left atrial diameter, even in patients without hypertension.

With respect to progression of AF in male and female patients with hypertension, distinct differences were ascertained regarding the effect of LVH (Figure 3). For male patients with hypertension, the AF progression rates differed significantly for those with and without LVH, with LVH being the only independent determinant of AF progression. However, in female patients, the progression rates in patients with and without LVH were similar. So the difference in AF progression seen in the overall group with hypertension is only attributable to the male patients, whereas LVH does not seem to play a role in the progression of AF in female hypertensive patients.

The dissimilar effect of LVH on AF progression in men and women could possibly be explained by the type of LVH. A cardiovascular magnetic resonance imaging study in 741 patients by Rider et al has shown that male patients predominantly show concentric LVH, whereas female patients show both concentric and eccentric LVH.²⁰ In another study of 64 middle-aged women with at least 10 years of treatment for hypertension, eccentric hypertrophy was more prevalent than concentric hypertrophy on echocardiography (42% vs 5%, $p < 0.001$, mean age 54 years).²¹ In a post hoc analysis of the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) trial, concentric LVH was found to be associated with AF recurrences in the rhythm control arm, whereas eccentric LVH was not associated with recurrences.²² This could be a consequence of diastolic dysfunction in concentric LVH, leading to elevation of filling pressures and left atrial dilatation. It has been shown that concentric LVH has a more profound negative effect on left atrial function and association with LA enlargement compared with eccentric LVH,²³ which could explain the effect seen on AF recurrences in the AFFIRM trial. One could argue that concentric LVH might therefore also be associated with AF progression, explaining the dissimilar effect of LVH on AF progression rates between genders in our population. Unfortunately, we were not able to assess the type of LVH in our population.

For female patients with hypertension, diastolic BP had a protective effect on AF progression. No previous studies have elaborated on this finding. However, Conen et al²⁴ report a higher incidence of new-onset AF in middle-aged women with a diastolic BP < 65 mm Hg and suggest a U-shaped association of diastolic BP and new-onset AF. Unfortunately, no male control group was present in this study.²⁴ It is possible that a low diastolic BP could also be associated with AF progression, like previously explained. In conclusion, more research is needed regarding gender differences in LVH and the progression of AF.

There are some limitations to the present study. First, we performed a post hoc subgroup analysis of the EHS. Therefore, the data presented in this study should be interpreted with care. This study was conducted in 2003 to 2004, yet the described outcomes are still relevant. Rhythm follow-up was performed in 47% of the included patients and the duration of follow-up was 1 year, limiting the number of AF progression events. In addition, LVH was a dichotomous parameter in the EHS, that is type of LVH was unknown and wall thicknesses were not reported in mm. Furthermore, some patients in the nonhypertensive group used medication like an angiotensin converting enzyme inhibitor, angiotensin

receptor blocker, dihydropyridine calcium antagonist or a diuretic. We were not able to assess whether these drugs were prescribed for hypertension or for another indication. Since in these patients hypertension was not checked as concomitant condition at time of conduct of the registry, they were classified as nonhypertensive in the present study. Last, women were underrepresented in this study.

In conclusion, in men with hypertension, LVH is associated with AF progression. This association seems to be absent in hypertensive women.

Disclosures

The investigators have no conflicts of interest to disclose.

Acknowledgment

We are grateful to the EHS team, national coordinators, investigators, and data collection officers for performing the survey. In addition, we are grateful to the sponsors of the EHS on Atrial Fibrillation: main sponsor AstraZeneca, major sponsor Sanofi (formerly known as Sanofi-Aventis), and sponsor Eucomed.

1. Manolis AJ, Rosei EA, Coca A, Cifkova R, Erdine SE, Kjeldsen S, Lip GY, Narkiewicz K, Parati G, Redon J, Schmieder R, Tsioufis C, Mancia G. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the working group 'hypertension arrhythmias and thrombosis' of the European Society of Hypertension. *J Hypertens* 2012;30:239–252.
2. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. *JAMA* 1994;271:840–844.
3. De Vos CB, Breithardt G, Camm AJ, Dorian P, Kowey PR, Le Heuzey JY, Naditch-Brule L, Prystowsky EN, Schwartz PJ, Torp-Pedersen C, Weintraub WS, Crijns HJ. Progression of atrial fibrillation in the Registry on Cardiac rhythm disorders assessing the control of atrial fibrillation cohort: clinical correlates and the effect of rhythm-control therapy. *Am Heart J* 2012;163:887–893.
4. de Vos CB, Pisters R, Nieuwlaar R, Prins MH, Tieleman RG, Coelen RJ, van den Heijkant AC, Allessie MA, Crijns HJ. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. *J Am Coll Cardiol* 2010;55:725–731.
5. Lip GY, Nieuwlaar R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. *Chest* 2010;137:263–272.
6. Gianfranchi L, Brignole M, Menozzi C, Lolli G, Bottoni N. Determinants of development of permanent atrial fibrillation and its treatment. *Europace* 1999;1:35–39.
7. Kerr CR, Humphries KH, Talajic M, Klein GJ, Connolly SJ, Green M, Boone J, Sheldon R, Dorian P, Newman D. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. *Am Heart J* 2005;149:489–496.
8. Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M, Avezum A, Diaz R, Hohnloser SH, Lewis BS, Shestakovska O, Wang J, Connolly SJ. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. *Eur Heart J* 2015;36:281–287a.
9. Vidal-Perez R, Otero-Ravina F, Lado-Lopez M, Turrado-Turrado V, Rodriguez-Moldes E, Gomez-Vazquez JL, de Frutos-de Marcos C, de Blas-Abad P, Besada-Gesto R, Gonzalez-Juanatey JR, Investigators B. The change in the atrial fibrillation type as a prognosis marker in a community study: long-term data from AFBAR (Atrial Fibrillation in the BARbanza) study. *Int J Cardiol* 2013;168:2146–2152.
10. Nieuwlaar R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, Cobbe S, Breithardt G, Le Heuzey JY, Prins MH, Levy S, Crijns HJ. European Heart Survey I. Atrial fibrillation management: a

- prospective survey in ESC member countries: the Euro Heart Survey on atrial fibrillation. *Eur Heart J* 2005;26:2422–2434.
11. Nieuwlaet R, Prins MH, Le Heuzey JY, Vardas PE, Aliot E, Santini M, Cobbe SM, Widdershoven JW, Baur LH, Levy S, Crijns HJ. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. *Eur Heart J* 2008;29:1181–1189.
 12. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. *BMJ* 2011;342:d124.
 13. Padfield GJ, Steinberg C, Swampillai J, Qian H, Connolly SJ, Dorian P, Green MS, Humphries KH, Klein GJ, Sheldon R, Talajic M, Kerr CR. Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian Registry of Atrial Fibrillation. *Heart Rhythm* 2017;14:801–807.
 14. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med* 2007;146:857–867.
 15. Hennersdorf MG, Schueller PO, Steiner S, Strauer BE. Prevalence of paroxysmal atrial fibrillation depending on the regression of left ventricular hypertrophy in arterial hypertension. *Hypertens Res* 2007;30:535–540.
 16. Schurgers LJ, Spronk HM. Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis. *Thromb Haemost* 2014;112:909–917.
 17. O'Neal WT, Efrid JT, Dawood FZ, Yeboah J, Alonso A, Heckbert SR, Soliman EZ. Coronary artery calcium and risk of atrial fibrillation (from the multi-ethnic study of atherosclerosis). *Am J Cardiol* 2014;114:1707–1712.
 18. Mitchell GF, Vasan RS, Keyes MJ, Parise H, Wang TJ, Larson MG, D'Agostino Sr. RB, Kannel WB, Levy D, Benjamin EJ. Pulse pressure and risk of new-onset atrial fibrillation. *JAMA* 2007;297:709–715.
 19. Blacher J, Staessen JA, Girerd X, Gasowski J, Thijs L, Liu L, Wang JG, Fagard RH, Safar ME. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. *Arch Intern Med* 2000;160:1085–1089.
 20. Rider OJ, Lewandowski A, Nethononda R, Petersen SE, Francis JM, Pitcher A, Holloway CJ, Dass S, Banerjee R, Byrne JP, Leeson P, Neubauer S. Gender-specific differences in left ventricular remodelling in obesity: insights from cardiovascular magnetic resonance imaging. *Eur Heart J* 2013;34:292–299.
 21. Paunovic K, Jakovljevic B, Stojanov V. Left ventricular hypertrophy in hypertensive obese women. *Acta Cardiol* 2006;61:623–629.
 22. Shah N, Badheka AO, Grover PM, Patel NJ, Chothani A, Mehta K, Hoosien M, Singh V, Savani GT, Deshmukh A, Rathod A, Patel N, Panaich SS, Arora S, Schwartz C, Blisker M, Coffey JO, Mitrani RD, Fuster V, Viles-Gonzalez JF. Influence of left ventricular remodeling on atrial fibrillation recurrence and cardiovascular hospitalizations in patients undergoing rhythm-control therapy. *Int J Cardiol* 2014;174:288–292.
 23. Tadic M, Cuspidi C, Pencic B, Kocijancic V, Celic V. The influence of left ventricular geometry on left atrial phasic function in hypertensive patients. *Blood Press* 2015;24:361–368.
 24. Conen D, Tedrow UB, Koplansky BA, Glynn RJ, Buring JE, Albert CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. *Circulation* 2009;119:2146–2152.